Photo of Hagop Kantarjian from mdanderson.org
Nov 6, 2023, 03:36
Hagop Kantarjian: Inotuzumab is safe and effective for the eradication of MRD in patients with B-cell ALL, with a MRD negativity rate of 69%
Hagop Kantarjian, Chair of MD Anderson Cancer Center, shared a post on Twitter:
Inotuzumab is safe and effective for the eradication of MRD in patients with B-cell ALL, with a MRD negativity rate of 69%.
Elias Jabbour, Fadi Haddad, Hagop Kantarjian of MD Anderson Cancer Center.
Elias Jabbour, Fadi Haddad, Hagop Kantarjian of MD Anderson Cancer Center.
For the article click here.
Source: Hagop Kantarjian/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 21, 2024, 12:36
Nov 21, 2024, 09:55
Nov 21, 2024, 09:28
Nov 21, 2024, 09:23
Nov 21, 2024, 09:04
Nov 21, 2024, 06:49